User profiles for Stephanie Vos
 | Stephanie VosDepartment of Psychiatry and Neuropsychology, Maastricht University Verified email at maastrichtuniversity.nl Cited by 6656 |
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
…, MM Verbeek, VL Villemagne, SJB Vos… - Jama, 2015 - jamanetwork.com
Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Background New research criteria for preclinical Alzheimer's disease have been proposed,
which include stages for cognitively normal individuals with abnormal amyloid markers (…
which include stages for cognitively normal individuals with abnormal amyloid markers (…
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage
Three sets of research criteria are available for diagnosis of Alzheimer’s disease in subjects
with mild cognitive impairment: the International Working Group-1, International Working …
with mild cognitive impairment: the International Working Group-1, International Working …
[HTML][HTML] Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia
Introduction In this multicenter study on subjective cognitive decline (SCD) in community-based
and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) …
and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) …
Suspected non-Alzheimer disease pathophysiology—concept and controversy
Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept
that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in …
that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in …
Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum
Importance One characteristic histopathological event in Alzheimer disease (AD) is cerebral
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the …
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers
of neurodegenerative dementias, enormous advancement has taken place in the field, …
of neurodegenerative dementias, enormous advancement has taken place in the field, …
Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia
…, E Stomrud, H Struyfs, CE Teunissen, SJB Vos… - JAMA …, 2018 - jamanetwork.com
Importance Cerebral amyloid-β aggregation is an early event in Alzheimer disease (AD).
Understanding the association between amyloid aggregation and cognitive manifestation in …
Understanding the association between amyloid aggregation and cognitive manifestation in …
[HTML][HTML] Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease
Background Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of
Alzheimer’s disease (AD) and is considered to result from neurodegeneration. T-tau levels, …
Alzheimer’s disease (AD) and is considered to result from neurodegeneration. T-tau levels, …
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI
Objective: To compare the predictive accuracy of β-amyloid (Aβ)1-42 and total tau in CSF,
hippocampal volume (HCV), and APOE genotype for Alzheimer disease (AD)-type dementia …
hippocampal volume (HCV), and APOE genotype for Alzheimer disease (AD)-type dementia …
